Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical firm Celgene has closed its $2.9 billion acquisition of Pharmion.
Subscribe to our email newsletter
Pharmion shareholders will receive $25 in cash and 0.84 Celgene shares for each share of Pharmion stock owned. The transaction brings together three medically meaningful therapies, Revlimid, Thalomid and Vidaza, treating patients worldwide.
Sol Barer, chairman and CEO of Celgene, said: “We believe our combined capabilities can maximize the clinical, regulatory and commercial potential of all of these programs.”